A model citizen? Is tamoxifen more effective than aromatase inhibitors if we pick the right patients?

J Natl Cancer Inst. 2008 May 7;100(9):610-3. doi: 10.1093/jnci/djn127. Epub 2008 Apr 29.
No abstract available

Publication types

  • Comment
  • Editorial
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antineoplastic Agents, Hormonal / therapeutic use*
  • Aromatase Inhibitors / therapeutic use*
  • Breast Neoplasms / chemistry
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / enzymology
  • Breast Neoplasms / genetics
  • Cytochrome P-450 CYP2D6 / genetics*
  • Cytochrome P-450 CYP2D6 Inhibitors*
  • Female
  • Humans
  • Middle Aged
  • Neoplasms, Hormone-Dependent / drug therapy
  • Neoplasms, Hormone-Dependent / genetics
  • Postmenopause
  • Receptors, Estrogen / analysis
  • Selective Estrogen Receptor Modulators / therapeutic use*
  • Tamoxifen / therapeutic use*

Substances

  • Antineoplastic Agents, Hormonal
  • Aromatase Inhibitors
  • Cytochrome P-450 CYP2D6 Inhibitors
  • Receptors, Estrogen
  • Selective Estrogen Receptor Modulators
  • Tamoxifen
  • Cytochrome P-450 CYP2D6